Guy P. Nohra
Managing General Partner @ Alta Life Sciences
Palo Alto, United States
Guy P. Nohra is a Series B investor at Alta Life Sciences in Palo Alto focused on Health Care and Biotechnology. Guy is a Managing Director of Alta Partners, and was also a partner at Burr, Egan, Deleage & Co., which he joined in 1989. Guy has been involved in the funding and development of notable medical technology and life science companies including Cutera, Innerdyne, R2 Technology, deCODE genetics, and Vesica.Previously, Guy was Product Manager ofMedical Products with Security Pacific Trading Corporation. He was responsible for a multi-million dollar product line and traveled extensively in Korea, Taiwan, Hong Kong, China and Southeast Asia.Currently, Guy serves on the board of directors of several private companies, including AcelRx, ATS Medical, Carbylan Biosurgery, Coapt Systems, Paracor Medical, PneumRx and Vertiflex, and is the Chairman of the Board of USGI Medical. He also serves on the board of directors of the Medical Device Manufacturing Association (MDMA). He was recently named to the Forbes "Midas List" of dealmakers in high-tech and life sciences. Guy also serves as the President of the Silicon Valley chapter of The Leukemia and Lymphoma Society.He holds a Master of Business Administration from the University of Chicago and a Bachelor of Arts in History from Stanford University.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Guy P. Nohra invests in
Stages Guy P. Nohra invests in
Countries Guy P. Nohra invests in
Investment Focus
Industry
- Health Care 4 (44%)
- Biotechnology 3 (33%)
- Medical Device 3 (33%)
- Medical 2 (22%)
- Hospital 1 (11%)
Stage
- Series B 3 (33%)
- Series A 2 (22%)
- Funding Round 2 (22%)
- Series C 1 (11%)
- Series D 1 (11%)
Country
- United States 4 (44%)
- Spain 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SANIFIT
|
SANIFIT is a biotechnology company focused on treatments for calcification disorders. | $60.6M / Series D / Jun 26, 2019 | |
Bionure
|
Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases. | $4.4M / Series A / May 17, 2018 | |
Carbylan Therapeutics
|
Carbylan Therapeutics was founded in 2004 with worldwide headquarters currently located in Palo Alto, California. They are a clinical-stage specialty pharmaceutical company focused on the development and commercialization of proprietary combination therapies. Our vision is to deliver best-in-class therapies to large growing markets where there is aclear unmet clinical need. | $6M / Jan 03, 2013 | |
PneumRx
|
PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $33M / Jan 04, 2011 | |
|
Carbylan Therapeutics
|
Carbylan Therapeutics was founded in 2004 with worldwide headquarters currently located in Palo Alto, California. They are a clinical-stage specialty pharmaceutical company focused on the development and commercialization of proprietary combination therapies. Our vision is to deliver best-in-class therapies to large growing markets where there is aclear unmet clinical need. | $20M / Series B / Nov 26, 2007 | |
|
PneumRx
|
PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $27M / Series B / Mar 06, 2007 | |
USGI Medical
|
USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $21M / Series C / Jul 01, 2006 | |
|
USGI Medical
|
USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $12M / Series B / Dec 15, 2003 | |
|
USGI Medical
|
USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $3.5M / Series A / Dec 01, 2001 |
Co-Investors
Adams Street Partners
2 deals together
Forbion Capital Partners
2 deals together
InterWest Partners
2 deals together
Spray Venture Partners
2 deals together
Telegraph Hill Partners
2 deals together
Criteria Venture Tech
1 deal together
About Alta Life Sciences
Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.
Alta Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Guy P. Nohra
Managing General Partner
|
|||
Scott Moonly
General Partner
|
|||
José Antonio Mesa
Partner
|
|||
Miguel Valls
General Partner
|
|||
Montserrat Vendrell
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Guy P. Nohra invest in?
Guy P. Nohra invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Guy P. Nohra last invest?
The most recent investment recorded for Guy P. Nohra closed in Jun 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
